---

Transaction Summary

• Completed reverse merger with Targacept in August 2015
• Catalyst is the surviving public entity now trading on the NASDAQ as "CBIO"
• Lead product, a Factor VIIa drug candidate for hemophilia, has successfully completed Phase I trials
• Catalyst is well-capitalized to advance its hemophilia drug into pivotal clinical trials

• South San Francisco, CA
• NASDAQ: CBIO


• Contact:
  Jeff Himawan
  
• www.catalystbiosciences.com

Related News

• Targacept and Catalyst Biosciences Enter Definitive Merger Agreement
• Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
• Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
• Catalyst Biosciences Announces Agreement with MedImmune to Develop Engineered Protease Therapeutics